UB Paderborn / Katalog / Suche / in CDI

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies

British journal of dermatology (1951), 2022-04, Vol.186 (4), p.642-651

2022

Link zum Volltext

Verfügbarkeit prüfen

Mast cells and basophils in cutaneous immune responses

Allergy (Copenhagen), 2015-02, Vol.70 (2), p.131-140

2015

Link zum Volltext

Verfügbarkeit prüfen

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

Journal of the European Academy of Dermatology and Venereology, 2016-10, Vol.30 (10), p.e89-e91

2016

Link zum Volltext

Verfügbarkeit prüfen

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.242-255

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled, phase II study

British journal of dermatology (1951), 2017-08, Vol.177 (2), p.419-427

2017

Link zum Volltext

Verfügbarkeit prüfen

Maculopapular-type drug eruptions caused by apalutamide: case series and a review of the literature

Journal of the European Academy of Dermatology and Venereology, 2022-02, Vol.36 (2), p.e113-e115

2022

Link zum Volltext

Verfügbarkeit prüfen

Polyenthesitis during treatment with dupilumab for atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, 2020-07, Vol.34 (7), p.e319-e321

2020

Link zum Volltext

Verfügbarkeit prüfen

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study

British journal of dermatology (1951), 2016-02, Vol.174 (2), p.296-304

2016

Link zum Volltext

Verfügbarkeit prüfen

Emergence of multiple revertant keratinocyte clones in a patient with KID syndrome

Journal of the European Academy of Dermatology and Venereology, 2024-03, Vol.38 (3), p.e285-e287

2024

Link zum Volltext

Verfügbarkeit prüfen

HPV‐29‐associated multiple hyperpigmented plaques mimicking solar lentigines on the lower legs

Journal of the European Academy of Dermatology and Venereology, 2022-09, Vol.36 (9), p.e697-e699

2022

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients

Journal of the European Academy of Dermatology and Venereology, 2019-02, Vol.33 (2), p.259-259

2019

Link zum Volltext

Verfügbarkeit prüfen

Light in the dark: distinct effects of dimethyl fumarate on different T‐cell subsets in psoriasis treatment

British journal of dermatology (1951), 2021-03, Vol.184 (3), p.389-390

2021

Link zum Volltext

Verfügbarkeit prüfen

Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells

Annals of oncology, 2016-03, Vol.27 (3), p.546-547

2016

Link zum Volltext

Verfügbarkeit prüfen

At‐risk circumstances for COVID‐19 increase the risk of pruritus: cross‐sectional and longitudinal analyses

Journal of the European Academy of Dermatology and Venereology, 2022-03, Vol.36 (3), p.e174-e175

2022

Link zum Volltext

Verfügbarkeit prüfen

Up‐dosing of nivolumab may induce serious immune‐related adverse events

Journal of the European Academy of Dermatology and Venereology, 2022-02, Vol.36 (2), p.e141-e142

2022

Link zum Volltext

Verfügbarkeit prüfen

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options

Journal of the European Academy of Dermatology and Venereology, 2022-09, Vol.36 (9), p.1432-1449

2022

Link zum Volltext

Verfügbarkeit prüfen

Serum thymus and activation‐regulated chemokine is a surrogate marker for bullous pemphigoid disease activity

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.e1125-e1127

2023

Link zum Volltext

Verfügbarkeit prüfen

Dupilumab improved atypical fibrotic skin plaques in atopic dermatitis

British journal of dermatology (1951), 2020-02, Vol.182 (2), p.487-488

2020

Link zum Volltext

Verfügbarkeit prüfen

Skin‐associated lymphoid tissue could be a sign of systemic disease: reply from authors

British journal of dermatology (1951), 2021-07, Vol.185 (1), p.233-234

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.39-51

2020

Link zum Volltext

Verfügbarkeit prüfen

Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (2), p.e133-e135

2021

Link zum Volltext

Verfügbarkeit prüfen

Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL‐17 inhibitors

Journal of the European Academy of Dermatology and Venereology, 2018-04, Vol.32 (4), p.e122-e123

2018

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous metastasis at the totally implantable venous access port site in a patient with pancreatic cancer

Journal of the European Academy of Dermatology and Venereology, 2022-07, Vol.36 (7), p.e572-e573

2022

Link zum Volltext

Verfügbarkeit prüfen

Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies

British journal of dermatology (1951), 2016-07, Vol.175 (1), p.187-190

2016

Link zum Volltext

Verfügbarkeit prüfen

Basal cell carcinoma on the ventral site of the finger with an intronic deletion of SUFU gene

Journal of the European Academy of Dermatology and Venereology, 2022-02, Vol.36 (2), p.e128-e130

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies

Mast cells and basophils in cutaneous immune responses

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled, phase II study

Maculopapular-type drug eruptions caused by apalutamide: case series and a review of the literature

Polyenthesitis during treatment with dupilumab for atopic dermatitis

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study

Emergence of multiple revertant keratinocyte clones in a patient with KID syndrome

HPV‐29‐associated multiple hyperpigmented plaques mimicking solar lentigines on the lower legs

Long‐term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients

Light in the dark: distinct effects of dimethyl fumarate on different T‐cell subsets in psoriasis treatment

Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells

At‐risk circumstances for COVID‐19 increase the risk of pruritus: cross‐sectional and longitudinal analyses

Up‐dosing of nivolumab may induce serious immune‐related adverse events

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options

Serum thymus and activation‐regulated chemokine is a surrogate marker for bullous pemphigoid disease activity

Dupilumab improved atypical fibrotic skin plaques in atopic dermatitis

Skin‐associated lymphoid tissue could be a sign of systemic disease: reply from authors

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials

Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019

Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL‐17 inhibitors

Subcutaneous metastasis at the totally implantable venous access port site in a patient with pancreatic cancer

Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies

Basal cell carcinoma on the ventral site of the finger with an intronic deletion of SUFU gene

Suchergebnisse filtern